Clinical trials: Infectious Encephalitis
Encephalitis, Japanese Encephalitis
Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers
This is a long-term follow-up of the persistence of immune response in participants who previously received a single dose of JE-CV at age 12 to 18 months in Study JEC02 (NCT00735644) .
- Trial name
- NCT01001988
- Testing
- Blood sample, JE-CV administered in Study JEC02
- Where
- 4 sites in Philippines, Thailand
- Volunteers
- 596 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Encephalitis, Tick-borne
Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR
The purpose of this study is to assess the safety of a vaccination schedule consisting of two vaccinations (21-35 days apart) with the tick-borne encephalitis (TBE) vaccine FSME-IMMUN NEW (5 consecutive lots) in comparison to…
- Trial name
- NCT00161824
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 7 sites in Poland
- Volunteers
- 3,800 people, healthy volunteers welcome
- Sponsor
- Pfizer
Toxoplasmosis, Cerebral, HIV Infections
Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis
To evaluate the efficacy, safety, and tolerance of atovaquone with either pyrimethamine or sulfadiazine in AIDS patients with toxoplasmic encephalitis.
- Trial name
- NCT00000794
- Testing
- Sulfadiazine, Clarithromycin, Atovaquone
- Where
- 16 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Progressive Multifocal Leukoencephalopathy, PML
Observational Study on Characteristics and Survival Correlates of Progressive Multifocal Leukoencephalopathy (PML) in Italy
The goal of this observational study is to learn about the features of Progressive Multifocal Leukoencephalopathy (PML) at the time of its diagnosis and the factors that may influence the outcome of persons with this disease.
- Trial name
- MI_PML (NCT06594614)
- Where
- Italy
- Volunteers
- 456 people
- Sponsor
- Scientific Institute San Raffaele
Japanese Encephalitis, Vaccine Preventable Disease
Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province
This study is to evaluate the seroprevalence of neutralizing antibodies against Japanese encephalitis (JE) virus in children aged 6 years who were previously administered with 5 different immunization strategies by JE attenuated…
- Conditions
- Japanese Encephalitis, Vaccine Preventable Disease, Vaccine Reaction
- Trial name
- NCT04817917
- Testing
- Japanese Encephalitis Vaccine (Vero Cell), Inactivated;, No prospective interventions
- Where
- 3 sites in China
- Volunteers
- 712 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention
Encephalitis, Tick-borne
FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years
The purpose of this study is to investigate the safety and immunogenicity of the third vaccination with one of three different concentrations of a TBE vaccine in all volunteers who completed two vaccinations in one of the three…
- Trial name
- NCT00161889
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 19 sites in Germany
- Volunteers
- 615 people, healthy volunteers welcome
- Sponsor
- Pfizer
Central European Encephalitis
Postencephalitic Symptoms After Tick Borne Encephalitis
The purpose of this study is to assess clinical outcome in patients with tick borne encephalitis.
- Trial name
- NCT00941590
- Where
- Slovenia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Ljubljana
Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy
Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia
This study will evaluate the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by John Cunningham virus (JCV), among people with multiple sclerosis who have been treated with ozanimod.
- Trial name
- NCT07732907
- Testing
- Ozanimod
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb